Highland Capital Management LLC Has $7.25 Million Position in Danaher Co. (NYSE:DHR)

Highland Capital Management LLC boosted its stake in shares of Danaher Co. (NYSE:DHR) by 9.5% during the 4th quarter, Holdings Channel reports. The institutional investor owned 31,333 shares of the conglomerate’s stock after buying an additional 2,725 shares during the quarter. Highland Capital Management LLC’s holdings in Danaher were worth $7,249,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Banco Santander S.A. acquired a new position in shares of Danaher in the 3rd quarter valued at about $683,000. Parkside Financial Bank & Trust lifted its stake in shares of Danaher by 4.8% in the 3rd quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock valued at $764,000 after purchasing an additional 142 shares during the period. Keybank National Association OH lifted its stake in shares of Danaher by 0.5% in the 3rd quarter. Keybank National Association OH now owns 553,155 shares of the conglomerate’s stock valued at $137,238,000 after purchasing an additional 2,567 shares during the period. Kingsview Wealth Management LLC increased its position in Danaher by 1.0% in the 3rd quarter. Kingsview Wealth Management LLC now owns 17,346 shares of the conglomerate’s stock valued at $4,303,000 after buying an additional 172 shares in the last quarter. Finally, Lcnb Corp increased its position in Danaher by 21.9% in the 2nd quarter. Lcnb Corp now owns 2,229 shares of the conglomerate’s stock valued at $535,000 after buying an additional 400 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Danaher

In related news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the transaction, the senior vice president now owns 38,102 shares of the company’s stock, valued at $9,601,704. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, SVP Daniel Raskas sold 23,757 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the transaction, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at $9,601,704. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Georgeann Couchara sold 2,622 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the transaction, the senior vice president now directly owns 4,244 shares in the company, valued at $1,029,891.48. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,957 shares of company stock valued at $8,265,802. 11.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts recently commented on DHR shares. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. HSBC began coverage on Danaher in a report on Monday, December 18th. They set a “hold” rating for the company. KeyCorp boosted their price objective on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Raymond James upped their target price on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Finally, Barclays lowered Danaher from an “overweight” rating to an “equal weight” rating and set a $240.00 target price for the company. in a report on Wednesday, January 24th. Seven research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average price target of $266.00.

Danaher Trading Up 0.2 %

NYSE:DHR opened at $248.84 on Thursday. The company has a market cap of $184.07 billion, a P/E ratio of 38.94, a P/E/G ratio of 3.77 and a beta of 0.84. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $259.00. The stock’s fifty day moving average price is $246.68 and its two-hundred day moving average price is $230.40. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.18. The firm had revenue of $6.41 billion for the quarter, compared to analysts’ expectations of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The business’s quarterly revenue was down 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.87 earnings per share. As a group, analysts expect that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio is presently 15.02%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.